Kim Tae Hyun, Kim Dae Yong, Park Joong-Won, Kim Young Il, Kim Seong Hoon, Park Hong Suk, Lee Woo Jin, Park Sang Jae, Hong Eun Kyung, Kim Chang-Min
Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Am J Clin Oncol. 2006 Dec;29(6):568-75. doi: 10.1097/01.coc.0000239147.60196.11.
To evaluate 3-dimensional conformal radiotherapy (3D-CRT) of unresectable hepatocellular carcinoma (HCC) patients for whom transcatheter arterial chemoembolization (TACE) was ineffective or unsuitable, and to determine whether tumor response and portal vein thrombosis (PVT) response to treatment were prognostic factors for overall survival.
From July 2001 to June 2005, 70 unresectable HCC patients were treated with 3D-CRT; PVT was present in 41 patients. A daily radiation dose ranging from 2 to 3 Gy was administered using 6 or 15 MV x-rays to deliver a total dose between 44 and 54 Gy.
Of 70 patients, follow-up computed tomography showed that primary tumor responses were complete response (CR) in 4 (5.7%) patients, partial response (PR) in 34 (48.6%), no response (NR) in 28 (37.1%), and progressive disease (PD) in 4 (8.6%). Of 41 patients with PVT, PVT responses were CR in 4 (9.7%) patients, PR in 12 (29.3%), NR in 20 (48.8%), and PD in 5 (12.2%). The median survival times were 18.0 and 20.1 month in the primary tumor and the PVT responders (CR + PR), respectively, which were longer than the 6.8 and 7.2 months in the primary tumor and the PVT nonresponders (NR + PD), respectively.
3D-CRT was associated with a 54.3% objective response rate for primary tumors and a 39.0% objective response rate for PVT. Both primary tumor and PVT responses were found to be prognostic factors for overall survival. The present results suggest 3D-CRT is a practical treatment option in HCC patients for whom TACE is ineffective or unsuitable.
评估经动脉化疗栓塞术(TACE)无效或不适用的不可切除肝细胞癌(HCC)患者的三维适形放疗(3D-CRT),并确定肿瘤反应和门静脉血栓形成(PVT)对治疗的反应是否为总生存的预后因素。
2001年7月至2005年6月,70例不可切除的HCC患者接受了3D-CRT治疗;41例患者存在PVT。使用6或15MV X射线给予每日2至3Gy的放射剂量,总剂量为44至54Gy。
70例患者中,随访计算机断层扫描显示,4例(5.7%)患者的原发性肿瘤反应为完全缓解(CR),34例(48.6%)为部分缓解(PR),28例(37.1%)无反应(NR),4例(8.6%)疾病进展(PD)。41例PVT患者中,4例(9.7%)患者的PVT反应为CR,12例(29.3%)为PR,20例(48.8%)为NR,5例(12.2%)为PD。原发性肿瘤和PVT反应者(CR+PR)的中位生存时间分别为18.0个月和20.1个月,分别长于原发性肿瘤和PVT无反应者(NR+PD)的6.8个月和7.2个月。
3D-CRT对原发性肿瘤的客观缓解率为54.3%,对PVT的客观缓解率为39.0%。原发性肿瘤和PVT反应均被发现是总生存预后因素。目前结果表明,3D-CRT是TACE无效或不适用的HCC患者的一种实用治疗选择。